Holen Sie sich die Stockscreener-App
0.1831
7.90%
-0.0157
Handel nachbörslich:
.18
-0.0031
-1.69%
Schlusskurs vom Vortag:
$0.1988
Offen:
$0.21075
24-Stunden-Volumen:
4.18M
Relative Volume:
0.51
Marktkapitalisierung:
$1.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.00429
EPS:
-42.6996
Netto-Cashflow:
$-4.67M
1W Leistung:
-35.80%
1M Leistung:
-82.22%
6M Leistung:
-81.69%
1J Leistung:
-86.34%
1-Tages-Spanne:
$0.1735
$0.217
1-Wochen-Bereich:
$0.1735
$0.3975
52-Wochen-Spanne:
$0.1735
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.1831 | 2.10M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind begins phase I/IIa trial for alcohol disorder drug at Hadassah - Investing.com Nigeria
What macro factors could drive Clearmind Medicine Inc. (CWY0) stock higherAnalyst Downgrade & Consistent Profit Trade Alerts - newser.com
Can Clearmind Medicine Inc. (CWY0) stock survive global slowdownSell Signal & High Return Trade Opportunity Guides - newser.com
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - The Manila Times
SciSparc: Neurothera Labs Announces Israeli Patent - GlobeNewswire
Clearmind begins phase I/IIa trial for alcohol disorder drug at Hadassah By Investing.com - Investing.com South Africa
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site - The Manila Times
Clearmind Medicine files Israeli patent for depression treatment - MSN
Will Clearmind Medicine Inc. stock reach all time highs in 2025July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Clearmind Medicine announces results from Phase I/IIa trial of CMND-100 - MSN
Clearmind Medicine Inc. (CMND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Clearmind Medicine Inc. stock keep outperforming rivals2025 Technical Overview & Accurate Intraday Trade Tips - newser.com
Can Clearmind Medicine Inc. (CWY0) stock double in coming yearsMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Why Clearmind Medicine Inc. stock could benefit from AI revolutionMarket Growth Review & Weekly Return Optimization Alerts - newser.com
Strategies to average down on Clearmind Medicine Inc.Analyst Upgrade & Breakout Confirmation Alerts - newser.com
How Clearmind Medicine Inc. stock performs after earningsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
How sentiment analysis helps forecast Clearmind Medicine Inc.Portfolio Profit Report & Safe Capital Growth Tips - newser.com
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - Yahoo Finance
Neurothera Labs and Clearmind Medicine File Patent for Innovative Depression Treatment - TipRanks
Why Clearmind Medicine Inc. (CWY0) stock gets analyst attentionWeekly Market Report & Daily Chart Pattern Signals - newser.com
Neurothera Labs and Clearmind Medicine File Israeli Patent for Non-Hallucinogenic Depression Treatment - citybuzz
Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025 - ts2.tech
Clearmind Medicine announces positive top-line results from first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder - MarketScreener
Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - Yahoo Finance
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):